15-min delayed · Sep 8, 3:45 PM ET · Get real-time quotes →
The Quantellect read.Of the 3 firms covering CareDx Inc, 1 rate it Buy or better, 2 sit at Hold, and 0 rate it Sell or worse, a moderate buy consensus. Targets range widely, $21.00 to $60.00 (about 2.9x), a sign of real disagreement on valuation. The average target of $42.33 sits 16% below the current $50.31. The rating mix has stayed broadly stable, with Buy-side ratings easing from 2 to 1 over recent months. On the fundamentals, the Street sees consensus EPS building from about $0.24 next quarter toward $1.33 the year after.Descriptive synthesis of third-party analyst data, not a Quantellect rating or recommendation.
ANALYST CONSENSUS3 ratings
Moderate Buy
Strong Buy00%
Buy133%
Hold267%
Sell00%
Strong Sell00%
Based on 3 analysts giving stock ratings to CareDx Inc.
As of Sep, 1 of 3 firms rate CDNA a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
CDNA EPS & revenue forecast
EPS · NEXT QUARTER
$0.24
Range $0.17 – $0.30 · 7 analysts · +101% YoY
Next period, 7 analysts expect CareDx Inc to earn $0.24 a share (range $0.17 – $0.30), versus $0.12 a year earlier. Full-year consensus is $1.20, growing to $1.33 the year after.
REVENUE · NEXT QUARTER
$123.6M
Range $122.1M – $124.4M · 7 analysts · +14% YoY
Revenue is expected to reach $123.6M (range $122.1M – $124.4M), +14.1% year-over-year. Full-year consensus is $495.1M, rising to $524.0M next year.
Top analysts covering CareDx Inc
Ranked by each analyst's overall Quantellect track record across all the stocks they cover, shown with their current call on CDNA.
#1
Matthew Sykes
Goldman Sachs · Rank #274
Buy
$26.00-48.3% to target
Overall win rate
38%
+ Follow
#2
Yi Chen
HC Wainwright & Co. · Rank #277
Hold
$46.00-8.6% to target
Overall win rate
33%
+ Follow
#3
Mark Massaro
BTIG
Buy
$60.00+19.3% to target
Coverage
—
+ Follow
#4
Brandon Couillard
Wells Fargo
Hold
$21.00-58.3% to target
Coverage
—
+ Follow
#5
MC
Mason Carrico
Stephens & Co.
Buy
$40.00-20.5% to target
Coverage
—
+ Follow
CDNA stock forecast FAQ
What is CDNA's average 12-month price target?+
The 3 analysts with a live target average $42.33 for CareDx Inc over the next 12 months, ranging from a $60.00 high to a $21.00 low.
Is CDNA stock a Buy, Sell or Hold right now?+
The current consensus is Moderate Buy. Of the 3 analyst ratings, 1 are Buy or Strong Buy, 2 are Hold, and 0 are Sell or Strong Sell.
What are the highest and lowest price targets for CDNA?+
The Street-high target is $60.00 (BTIG), and the Street-low is $21.00 (Wells Fargo). The average of all 3 active targets is $42.33.
How many Wall Street analysts cover CDNA?+
3 analysts have an active rating on CareDx Inc, and 3 firms carry a live 12-month price target.
Who is the most accurate analyst covering CDNA?+
Among analysts who currently cover CDNA, Matthew Sykes of Goldman Sachs has the strongest overall Quantellect track record (Rank #274). Their current call is Buy with a $26.00 target.
What is CareDx Inc's projected EPS for next quarter?+
The consensus estimate is $0.24 per share (range $0.17 – $0.30) across 7 analysts. Full-year EPS is projected at $1.20, rising to $1.33 the following year.
How much revenue is CareDx Inc expected to report next quarter?+
Consensus revenue is $123.6M (range $122.1M – $124.4M). Full-year revenue is projected at $495.1M, growing to $524.0M next year.
Have analysts been upgrading or downgrading CDNA lately?+
As of Sep, 1 of 3 firms rate CDNA a Buy (2 Hold, 0 Sell), the standing distribution of every covering firm's most recent active call.
How are the analysts on this page ranked?+
By each analyst's overall Quantellect track record — a sample-adjusted measure of how accurate their calls have been across every stock they cover. We do not rank on their CDNA calls alone, since a single stock is too small a sample to be reliable.
Which data on this page is live, and how often does it update?+
Price and daily change are 15-minute delayed market data. Analyst ratings, targets, consensus and earnings estimates are aggregated from multiple data providers and refresh daily.
Disclaimer: Ratings, price targets, consensus and earnings estimates on this page describe third-party analyst research aggregated from multiple data providers and refreshed daily; price and daily change are 15-minute delayed. These are historical opinions, not recommendations, and nothing on this page, including The Quantellect read, is a rating, a price target, or investment advice from Quantellect. Always do your own research and consult a licensed financial advisor before making investment decisions.
